|
1
|
Saâda E, Follana P, Peyrade F, Mari V and
François E: Pathogenesis and management of refractory malignant
ascites. Bull Cancer. 98:679–687. 2011.(In French). PubMed/NCBI
|
|
2
|
Smith EM and Jayson GC: The current and
future management of malignant ascites. Clin Oncol (R Coll Radiol).
15:59–72. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung M and Kozuch P: Treatment of
malignant ascites. Curr Treat Options Oncol. 9:215–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Becker G, Galandi D and Blum HE: Malignant
ascites: systematic review and guideline for treatment. Eur J
Cancer. 42:589–597. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pourgholami MH, Yan Cai Z, Lu Y, Wang L
and Morris DL: Albendazole: a potent inhibitor of vascular
endothelial growth factor and malignant ascites formation in
OVCAR-3 tumor-bearing nude mice. Clin Cancer Res. 12:1928–1935.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Agarwal A, Covic L, Sevigny LM, et al:
Targeting a metalloprotease-PAR1 signaling system with
cell-penetrating pepducins inhibits angiogenesis, ascites and
progression of ovarian cancer. Mol Cancer Ther. 7:2746–2757. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beattie GJ and Smyth JF: Phase I study of
intraperitoneal metalloproteinase inhibitor BB94 in patients with
malignant ascites. Clin Cancer Res. 4:1899–1902. 1998.PubMed/NCBI
|
|
8
|
Kobold S, Hegewisch-Becker S, Oechsle K,
Jordan K, Bokemeyer C and Atanackovic D: Intraperitoneal VEGF
inhibition using bevacizumab: a potential approach for the
symptomatic treatment of malignant ascites? Oncologist.
14:1242–1251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Reilly MS, Boehm T, Shing Y, et al:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Folkman J: Antiangiogenesis in cancer
therapy - endostatin and its mechanisms of action. Exp Cell Res.
312:594–607. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thomas JP, Arzoomanian RZ, Alberti D, et
al: Phase I pharmacokinetic and pharmacodynamic study of
recombinant human endostatin in patients with advanced solid
tumors. J Clin Oncol. 21:223–231. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herbst RS, Hess KR, Tran HT, et al: Phase
I study of recombinant human endostatin in patients with advanced
solid tumors. J Clin Oncol. 20:3792–3803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang X, Wong MK, Zhao Q, et al: Soluble
recombinant endostatin purified from Escherichia coli:
antiangiogenic activity and antitumor effect. Cancer Res.
61:478–481. 2001.PubMed/NCBI
|
|
14
|
Han B, Xiu Q, Wang H, et al: A
multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy of paclitaxel-carboplatin alone or with
Endostar for advanced non-small cell lung cancer. J Thorac Oncol.
6:1104–1109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun L, Ye HY, Zhang YH, Guan YS and Wu H:
Epidermal growth factor receptor antibody plus recombinant human
endostatin in treatment of hepatic metastases after remnant gastric
cancer resection. World J Gastroenterol. 13:6115–6118. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lehmenkühler A: Spreading depression -
cortical reactions: disorders of the extracellular
microenvironment. EEG EMG Z Elektroenzephalogr Elektromyogr
Verwandte Geb. 21:1–6. 1990.(In German). PubMed/NCBI
|
|
17
|
Ayhan A, Gultekin M, Taskiran C, et al:
Ascites and epithelial ovarian cancers: a reappraisal with respect
to different aspects. Int J Gynecol Cancer. 17:68–75. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan F, Chen Y, Dellian M, Safabakhsh N,
Ferrara N and Jain RK: Time-dependent vascular regression and
permeability changes in established human tumor xenografts induced
by an anti-vascular endothelial growth factor/vascular permeability
factor antibody. Proc Natl Acad Sci USA. 93:14765–14770. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai YJ, Zheng DY, Luo RC, et al: Avastin
combined with cisplan inhibits malignant ascites production in nude
mice bearing transplanted ovary carcinoma with high VEGF
expression. Nan Fang Yi Ke Da Xue Xue Bao. 27:647–649. 2007.(In
Chinese). PubMed/NCBI
|
|
20
|
Hirayama N, Tabata C, Tabata R, et al:
Pleural effusion VEGF levels as a prognostic factor of malignant
pleural mesothelioma. Respir Med. 105:137–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishimoto O, Saijo Y, Narumi K, et al: High
level of vascular endothelial growth factor in hemorrhagic pleural
effusion of cancer. Oncology. 63:70–75. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Verheul HM, Hoekman K, Jorna AS, Smit EF
and Pinedo HM: Targeting vascular endothelial growth factor
blockade: ascites and pleural effusion formation. Oncologist.
5:(Suppl 1). 45–50. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tepper D: Frontiers in congestive heart
failure: consumption of NSAIDs and the development of congestive
heart failure in elderly patients: an underrecognized public health
problem. Congest Heart Fail. 6:168–169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ling Y, Yang Y, Lu N, et al: Endostar, a
novel recombinant human endostatin, exerts antiangiogenic effect
via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of
endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han Q, Fu Y, Zhou H, He Y and Luo Y:
Contributions of Zn(II)-binding to the structural stability of
endostatin. FEBS Lett. 581:3027–3032. 2007. View Article : Google Scholar : PubMed/NCBI
|
